Agilent Technologies, Inc. $A Position Increased by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 39.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 699,305 shares of the medical research company’s stock after purchasing an additional 197,372 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.25% of Agilent Technologies worth $82,555,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. J.W. Cole Advisors Inc. grew its position in shares of Agilent Technologies by 10.7% during the second quarter. J.W. Cole Advisors Inc. now owns 2,610 shares of the medical research company’s stock worth $308,000 after acquiring an additional 252 shares during the last quarter. Advisors Asset Management Inc. boosted its stake in Agilent Technologies by 24.0% during the 2nd quarter. Advisors Asset Management Inc. now owns 8,474 shares of the medical research company’s stock valued at $1,000,000 after purchasing an additional 1,639 shares during the period. Financial Advocates Investment Management grew its position in Agilent Technologies by 5.9% in the 2nd quarter. Financial Advocates Investment Management now owns 3,299 shares of the medical research company’s stock worth $389,000 after purchasing an additional 184 shares during the last quarter. Edmond DE Rothschild Holding S.A. grew its position in Agilent Technologies by 7.8% in the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 40,657 shares of the medical research company’s stock worth $4,798,000 after purchasing an additional 2,958 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC increased its stake in shares of Agilent Technologies by 1.7% in the second quarter. Steward Partners Investment Advisory LLC now owns 6,443 shares of the medical research company’s stock valued at $760,000 after purchasing an additional 110 shares during the period. 87.41% of the stock is owned by institutional investors and hedge funds.

Agilent Technologies Trading Down 1.7%

Shares of A stock opened at $154.52 on Thursday. The stock has a 50-day simple moving average of $141.36 and a 200 day simple moving average of $126.23. The stock has a market capitalization of $43.81 billion, a P/E ratio of 36.27, a P/E/G ratio of 4.67 and a beta of 1.29. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $160.27. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Monday, November 24th. The medical research company reported $1.59 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.01. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The company had revenue of $1.86 billion during the quarter, compared to the consensus estimate of $1.83 billion. During the same period in the prior year, the company earned $1.46 EPS. Agilent Technologies’s revenue was up 9.4% on a year-over-year basis. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS. FY 2026 guidance at 5.860-6.000 EPS. On average, sell-side analysts expect that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 28th. Investors of record on Tuesday, January 6th will be issued a dividend of $0.255 per share. The ex-dividend date is Tuesday, January 6th. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.25. This represents a $1.02 dividend on an annualized basis and a yield of 0.7%. Agilent Technologies’s payout ratio is 23.94%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. TD Cowen boosted their price target on Agilent Technologies from $150.00 to $162.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. Barclays raised their price target on Agilent Technologies from $145.00 to $165.00 and gave the company an “equal weight” rating in a report on Tuesday. Evercore ISI upped their price objective on shares of Agilent Technologies from $128.00 to $140.00 and gave the stock an “in-line” rating in a report on Tuesday, October 7th. Finally, Bank of America increased their target price on shares of Agilent Technologies from $150.00 to $165.00 and gave the company a “neutral” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $161.08.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 12,490 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $150.00, for a total value of $1,873,500.00. Following the transaction, the chief executive officer owned 33,448 shares of the company’s stock, valued at approximately $5,017,200. This represents a 27.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.26% of the company’s stock.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.